SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease.
2021
Over the past 40 years there has been a steady rise in the number of people with chronic kidney disease due mainly to a significant increase in the number of people with diabetic kidney disease (DKD). Current treatments (blood pressure control, blood sugar control, and renin-angiotensin-aldosterone system inhibitors) have had a significant impact on slowing progression of DKD. But the continued rise illustrates that there is a great need for new medications. Recently, a number of potentially reno-protective medicines have been studied. In this review, these new medications are discussed with respect to both their reported benefits and possible risks.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
74
References
0
Citations
NaN
KQI